2024
Image representation for cutaneous drug reactions in darker skin types in undergraduate medical education resources
Bassir F, Swallow M, Valido K, Ahmad M, Nelson C, Perkins S. Image representation for cutaneous drug reactions in darker skin types in undergraduate medical education resources. Archives Of Dermatological Research 2024, 317: 105. PMID: 39666138, DOI: 10.1007/s00403-024-03544-6.Peer-Reviewed Original ResearchDrug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective
Baptista A, Macedo A, Marreiros A, Coelho A, Perazella M. Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective. Journal Of Clinical Medicine 2024, 13: 4869. PMID: 39201010, PMCID: PMC11355908, DOI: 10.3390/jcm13164869.Peer-Reviewed Original ResearchGlomerular disordersAdverse drug reactionsPotential nephrotoxinsNephrotoxic potentialDrug reactionsDisproportion indexNotifications of adverse drug reactionsAssociated with medicationsAssociated with drug useNephrotoxic drugsOver-the-counter drugsNon-nephrotoxicMethods:</b>Physiopathological mechanismsOver-the-counterNephrotoxic rolePrescribed medicationsSpontaneous notificationsVigiBaseDrug useEvaluate medicationsMedicationMedication useNephrotoxinsDrugTreatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach
Valido K, Patel V, Murphy M, Junejo M, Patel D, Deutsch A, Turner N, Zaki T, King B, Damsky W, Nelson C. Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach. JAAD Case Reports 2024, 48: 49-53. PMID: 38774671, PMCID: PMC11107093, DOI: 10.1016/j.jdcr.2024.03.020.Peer-Reviewed Original ResearchComparison of agranulocytosis and anti‐neutrophil cytoplasmic antibody‐associated vasculitis caused by two antithyroid drugs: A pharmacovigilance study using the WHO international database
Han J, Lee J, Jung Y, Kim M, Lee S, Kronbichler A, Tizaoui K, Koyanagi A, Kim E, Song K, Chae H, Yon D, Shin J, Smith L. Comparison of agranulocytosis and anti‐neutrophil cytoplasmic antibody‐associated vasculitis caused by two antithyroid drugs: A pharmacovigilance study using the WHO international database. Fundamental & Clinical Pharmacology 2024, 38: 780-788. PMID: 38342499, DOI: 10.1111/fcp.12991.Peer-Reviewed Original ResearchConceptsAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitisAdverse drug reactionsAssociated with MMICases of adverse drug reactionsAntithyroid drugsAnti-neutrophil cytoplasmic antibody-associated vasculitisAntibody (ANCA)-associated vasculitisAssociated with high morbidityCase/non-case analysisCases of agranulocytosisAntibody-associated vasculitisAdverse drug effectsAgranulocytosis casesAnti-neutrophilDrug withdrawalAgranulocytosisHigh morbidityCase/non-caseDrug effectsPharmacovigilance databaseIndividual case safety reportsDrug reactionsPropylthiouracilDisproportionality analysisPharmacovigilance studiesDischarge Information About Adverse Drug Reactions Indicates Lower Self-Reported Adverse Drug Reactions and Fewer Concerns in Patients After Percutaneous Coronary Intervention
Pettersen T, Schjøtt J, Allore H, Bendz B, Borregaard B, Fridlund B, Hadjistavropoulos H, Larsen A, Nordrehaug J, Rasmussen T, Rotevatn S, Valaker I, Wentzel-Larsen T, Norekvål T, Investigators C. Discharge Information About Adverse Drug Reactions Indicates Lower Self-Reported Adverse Drug Reactions and Fewer Concerns in Patients After Percutaneous Coronary Intervention. Heart Lung And Circulation 2024, 33: 350-361. PMID: 38238118, DOI: 10.1016/j.hlc.2023.12.005.Peer-Reviewed Original ResearchSelf-reported adverse drug reactionsPrescribed pharmacotherapyPotential adverse drug reactionsAdverse drug reactionsPercutaneous coronary interventionPatient-reported outcome measuresCovariate-adjusted logistic regressionConfidence intervalsNational quality registryProspective multicentre cohort studyAssociated with incidencePatients' medical recordsIntervention aimHealthcare providersQuality registryMulticentre cohort studyDischarge informationDrug reactionsInformation patientsOdds ratioOutcome measuresCohort studyHospital dischargeLogistic regressionPCI centre
2023
Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS
Dai M, Dou X, Chen M, Yang J, Long J, Lin Y. Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS. Naunyn-Schmiedeberg's Archives Of Pharmacology 2023, 397: 4105-4121. PMID: 38032491, DOI: 10.1007/s00210-023-02844-4.Peer-Reviewed Original ResearchAcute adverse drug reactionsEmpirical Bayesian geometric meanAdverse eventsSystem organ classReporting odds ratioProportional reporting ratioAdverse Event Reporting System databaseFDA Adverse Event Reporting System (FAERS) databaseSevere cancer painAdverse drug reactionsNervous system disordersReal-world studyUS FDA Adverse Event Reporting System (FAERS) databaseReporting System databasePostoperative analgesiaCancer painRespiratory depressionChronic painToxic leukoencephalopathyGeneral anesthesiaMediastinal diseaseDrug reactionsMediastinal disordersOdds ratioRespiratory disordersSex differences in incidence of self-reported adverse drug reactions after percutaneous coronary intervention
Pettersen T, Schjott J, Allore H, Bendz B, Borregaard B, Fridlund B, Hadjistavropoulos H, Larsen A, Nordrehaug J, Rasmussen T, Rotevatn S, Valaker I, Wentzel-Larsen T, Norekval T. Sex differences in incidence of self-reported adverse drug reactions after percutaneous coronary intervention. European Heart Journal 2023, 44: ehad655.2879. DOI: 10.1093/eurheartj/ehad655.2879.Peer-Reviewed Original ResearchSelf-reported adverse drug reactionsPercutaneous coronary interventionAdverse drug reactionsPotential adverse drug reactionsPrescribed therapyCoronary interventionHospital dischargeDrug reactionsMedical recordsOdds ratioIncidence of ADRsProspective multicentre cohort studyMore adverse drug reactionsMulticentre cohort studyAcute coronary syndromeSex differencesTotal study populationConfidence intervalsPatients' medical recordsClinical drug trialsProportion of womenHeart ContinuityCoronary syndromeCohort studyPCI centerIncidence of Severe Adverse Drug Reactions to Ultrasound Enhancement Agents in a Contemporary Echocardiography Practice
Ali M, Johnson M, Irwin T, Henry S, Sugeng L, Kansal S, Allison T, Bremer M, Jones V, Martineau M, Wong C, Marecki G, Stebbins J, Michelena H, McCully R, Svatikova A, Padang R, Scott C, Kanuga M, Arsanjani R, Pellikka P, Kane G, Thaden J. Incidence of Severe Adverse Drug Reactions to Ultrasound Enhancement Agents in a Contemporary Echocardiography Practice. Journal Of The American Society Of Echocardiography 2023, 37: 276-284.e3. PMID: 37879379, DOI: 10.1016/j.echo.2023.10.010.Peer-Reviewed Original ResearchConceptsUltrasound enhancing agentsAdverse drug reactionsSevere adverse drug reactionsDrug reactionsEchocardiography databaseHealth systemFrequency of severe adverse drug reactionsIsolated back painUS health systemST-segment elevationIncidence of severe adverse drug reactionsLoss of pulseCardiopulmonary involvementLoss of consciousnessMRNA vaccinesLumasonMatched ControlsRare riskEnhancing agentsADR rateProspective reportsCOVID-19 vaccineAdministrationPainHeadacheComprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions
van der Horst M, Meijer Y, de Boer N, Guloksuz S, Hasan A, Siskind D, Wagner E, consortium C, Müderrisoğlu A, Privat A, Bouhuis A, Hasan A, Jongkind A, Gonzalez-Pinto A, Santacana A, D'Agostino A, Ertugrul A, Yağcioğlu A, Crespo-Facorro B, Sanchez-Barbero B, Spuch C, Morgenroth C, de Pinedo C, Casetta C, Bousman C, Pantelis C, Ovejas-Catalán C, Garcia-Rizo C, Okhuijsen-Pfeifer C, Cohen D, Ristic D, Beld E, Repo-Tiihonen E, Wagner E, Jeger-Land E, Vilella E, Bekema E, Sepúlveda S, Seghi F, Wiedenmann F, Martini F, Serio F, Vairano F, Mercuriali G, Boido G, Yoca G, van Beek H, Gijsman H, Tuppurainen H, Everall I, Novakovic I, Zorrilla I, Erdoğan I, Sapienza J, Bogers J, Tiihonen J, Vázquez-Bourgon J, van Os J, Schneider-Thoma J, Luykx J, Grootens K, Mar-Barrutia L, Martorell L, Bak M, Spangaro M, de Vos M, de Koning M, Garriga M, Lähteenvuo M, Bosia M, van der Horst M, Babaoğlu M, Veereschild M, Manchia M, Edlinger M, Fuentes-Pérez P, Paribello P, Lopez-Pena P, Kahn R, Cavallaro R, Veerman S, Gutwinski S, Schreiter S, Ripke S, Baltanás T, Oviedo-Salcedo T, Hallikainen T, Görlitz T, Alink W, Ayhan Y, Okhuijsen-Pfeifer C, Luykx J. Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Research 2023, 330: 115539. PMID: 37988817, DOI: 10.1016/j.psychres.2023.115539.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsClinical factorsDrug reactionsPrevalence ratesCommon adverse drug reactionsWeight gainSignificant weight gainMulti-center studyImproved treatment outcomesClozapine blood levelsClozapine monotherapyClozapine treatmentLower BMIBlood levelsTreatment outcomesHigh prevalencePrevalenceMean numberYounger participantsSex differencesParticipantsTreatmentComprehensive dissectionConstipationHypersalivationmHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study
Cossio A, Bautista-Gomez M, Alexander N, Del Castillo A, del Mar Castro M, Castaño-Grajales P, Gutiérrez-Poloche Y, Zuluaga L, Vargas-Bernal L, Navarro A, Saravia N. mHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study. American Journal Of Tropical Medicine And Hygiene 2023, 109: 778-790. PMID: 37640290, PMCID: PMC10551068, DOI: 10.4269/ajtmh.22-0805.Peer-Reviewed Original ResearchConceptsCommunity health leadersProportion of patientsAdverse drug reactionsCutaneous leishmaniasisDrug reactionsTherapeutic responseHealth workersCutaneous leishmaniasis patientsInitiation of treatmentAnti-leishmanial treatmentStandard of careGlobal health problemMobile health strategiesEffectiveness of treatmentPublic health needsLeishmaniasis patientsCare groupTreatment adherenceHealth strategiesMHealth interventionsPatientsHealth problemsHealth needsMHealth strategiesCase identificationDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. Journal Of The American Academy Of Dermatology 2023, 90: 911-926. PMID: 37516356, DOI: 10.1016/j.jaad.2023.02.073.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsCutaneous adverse reactionsSystemic symptomsDrug reactionsAdverse reactionsDifferential diagnosisDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromeDiHS/DRESSVisceral organ involvementSteroid-sparing agentCornerstone of managementFirst-line therapyEvidence-based overviewSystemic corticosteroidsHypersensitivity syndromeImmediate discontinuationOrgan involvementRisk stratificationAutoimmune diseasesAdjunctive testNeoplastic disordersDiagnostic criteriaLongitudinal evaluationDiagnosisDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. Journal Of The American Academy Of Dermatology 2023, 90: 885-908. PMID: 37516359, DOI: 10.1016/j.jaad.2023.02.072.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsDiHS/DRESSClinicopathological featuresSystemic symptomsDrug reactionsDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromePart I. EpidemiologyVisceral organ involvementCutaneous adverse reactionsRisk of relapseHypersensitivity syndromeOrgan involvementI. EpidemiologyOrgan dysfunctionSignificant morbidityAutoimmune diseasesAdverse reactionsDrug exposureT cellsCommon triggerImmune systemPathogenesisEosinophiliaMedical education activitiesDelayed Intradermal Skin Testing to Diagnose Culprits Drugs in Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)
Kwah J, Banerji A. Delayed Intradermal Skin Testing to Diagnose Culprits Drugs in Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS). The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 1572-1573. PMID: 37150547, DOI: 10.1016/j.jaip.2023.02.013.Peer-Reviewed Case Reports and Technical Notes
2022
Informing patients about potential adverse drug reactions after percutaneous coronary intervention reduces the occurrence of self-reported adverse drug reactions
Pettersen T, Schjott J, Allore H, Bendz B, Borregaard B, Fridlund B, Hadjistavropoulos H, Larsen A, Nordrehaug J, Rasmussen T, Rotevatn S, Valaker I, Wentzel-Larsen T, Norekval T. Informing patients about potential adverse drug reactions after percutaneous coronary intervention reduces the occurrence of self-reported adverse drug reactions. European Heart Journal 2022, 43: ehac544.2736. DOI: 10.1093/eurheartj/ehac544.2736.Peer-Reviewed Original ResearchSelf-reported adverse drug reactionsPercutaneous coronary interventionAdverse drug reactionsPotential adverse drug reactionsHospital dischargePrescribed therapyDrug reactionsCoronary interventionMedical recordsOdds ratioIncidence of ADRsProspective multicentre cohort studyStable coronary artery diseaseMulticentre cohort studyCoronary artery diseaseConfidence intervalsPatients' medical recordsHeart ContinuityInforming PatientsMore comorbiditiesIndex hospitalizationCohort studyArtery diseasePCI centerClinical variablesA Text Mining Protocol for Predicting Drug–Drug Interaction and Adverse Drug Reactions from PubMed Articles
Shukkoor M, Raja K, Baharuldin M. A Text Mining Protocol for Predicting Drug–Drug Interaction and Adverse Drug Reactions from PubMed Articles. Methods In Molecular Biology 2022, 2496: 237-258. PMID: 35713868, DOI: 10.1007/978-1-0716-2305-3_13.Peer-Reviewed Original ResearchConceptsPredicting drug-drug interactionsRetrieval of dataPubMed abstractsDrug-drug interactionsAdverse drug reactionsAutomated techniqueBiomedical literatureKnowledge of drug-drug interactionsScientific publicationsPubMed articlesHealth care costsDrug reactionsCare costsSusceptible individualsManual retrievalInformationClinical outcomesA Text Mining Protocol for Extracting Drug–Drug Interaction and Adverse Drug Reactions Specific to Patient Population, Pharmacokinetics, Pharmacodynamics, and Disease
Shukkoor M, Baharuldin M, Raja K. A Text Mining Protocol for Extracting Drug–Drug Interaction and Adverse Drug Reactions Specific to Patient Population, Pharmacokinetics, Pharmacodynamics, and Disease. Methods In Molecular Biology 2022, 2496: 259-282. PMID: 35713869, DOI: 10.1007/978-1-0716-2305-3_14.Peer-Reviewed Original ResearchNeutrophilic Dermatoses: a Clinical Update
Weiss EH, Ko CJ, Leung TH, Micheletti RG, Mostaghimi A, Ramachandran SM, Rosenbach M, Nelson CA. Neutrophilic Dermatoses: a Clinical Update. Current Dermatology Reports 2022, 11: 89-102. PMID: 35310367, PMCID: PMC8924564, DOI: 10.1007/s13671-022-00355-8.Peer-Reviewed Original ResearchNeutrophilic eccrine hidradenitisSterile neutrophilic infiltratesAnti-inflammatory therapyAbnormal neutrophil functionRecent FindingsRecent studiesNeutrophilic dermatosisSweet's syndromeBehçet's syndromeClinicopathological featuresNeutrophilic infiltrateSignificant morbidityClinical updateNeutrophil functionComplex pathogenesisDrug reactionsExtracutaneous manifestationsInflammasome activationNeoplastic disordersGenetic predispositionMalignant transformationDermatosesSyndromePathogenesisTherapeutic frameworkDisordersDolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report)
Adeiza M, Kekulah I, Wachekwa I, Ogbuagu O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report). PAMJ Clinical Medicine 2022, 8 DOI: 10.11604/pamj-cm.2022.8.47.33930.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAdverse drug reactionsDrug reactionsHIV programsResource-limited settingsAntiretroviral therapyHypersensitivity reactionsAdvanced HIV diseaseLamivudine/tenofovirLamivudine/zidovudineRoutine laboratory monitoringCombination antiretroviral therapyAntiretroviral drug treatmentFirst-line cARTFeatures of anaphylaxisRelevant health educationDrug discontinuityViral suppressionHIV diseaseHIV infectionBlood workOpportunistic infectionsLaboratory monitoringNew symptomsDrug treatmentMedical treatment
2021
Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Lee S, Yang J, Jung S, Kim M, Yon D, Lee S, Kang H, Dragioti E, Tizaoui K, Jacob L, Koyanagi A, Salem J, Kostev K, Lascu A, Shin J, Kim J, Smith L. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports. European Review For Medical And Pharmacological Sciences 2021, 25: 7390-7397. PMID: 34919240, DOI: 10.26355/eurrev_202112_27435.Peer-Reviewed Original ResearchConceptsAdverse reactionsIndividual case safety reportsReal-world settingsWorld Health Organization databaseCase safety reportsWHO global database of individual case safety reportsSafety reportsPharmacovigilance cohort studyNeural network methodAdverse drug reactionsAssociated with remdesivirBayesian neural network methodCohort studyPandemic outbreak of coronavirus disease 2019Clinical benefitWHO global databaseTreatment of COVID-19Remdesivir useDrug reactionsInformation componentNeuropsychological dysfunctionGS-5734Pharmacovigilance signalsCoronavirus disease 2019Outbreak of coronavirus disease 2019Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database
Jung Y, Kim M, Li H, Lee K, Koyanagi A, Solmi M, Kronbichler A, Dragioti E, Tizaoui K, Cargnin S, Terrazzino S, Hong S, Ghayda R, Kim N, Chung S, Jacob L, Salem J, Yon D, Lee S, Kostev K, Kim A, Jung J, Choi J, Shin J, Park S, Choi S, Ban K, Moon S, Go Y, Shin J, Smith L. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clinical And Translational Science 2021, 15: 501-513. PMID: 34719115, PMCID: PMC8841455, DOI: 10.1111/cts.13168.Peer-Reviewed Original ResearchConceptsFood and Drug AdministrationAdverse drug reactionsAssociated with remdesivirHPSC-CMsWorld Health OrganizationUS Food and Drug AdministrationInternational pharmacovigilance databaseAnalysis to patientsDose-dependent mannerIn vitro dataCV-ADRTreatment of coronavirus disease 2019Cardiovascular eventsCardiac arrestOdds ratioPharmacovigilance databaseRemdesivir useIn vitro experimentsDrug reactionsDisproportionality analysisDrug AdministrationMultiple confoundersCV consequencesCV monitoringCoronavirus disease 2019
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply